We are pleased to announce that on December 15th ICE Pharma completed the acquisition of ABC Farmaceutici S.p.A (“ABC”). ABC is a pharmaceutical company based in Ivrea, Italy. Founded in 1925, the company is dedicated to the research, development, production and sale of pharmaceutical products and active ingredients. Almost 100 years of activity and commitment to its patients have allowed ABC to obtain international patents in gastroenterology and pulmonology medical specialisations, as well as important global partnerships for the contract manufacture of several pharmaceutical formulations.
The highly complementary combination of ICE Pharma and ABC will drive strategic commercial and industrial synergies, consistent with the aim of providing added value to our customers through a vertically integrated value chain for UDCA finished dosage form (FDF) production, best in class quality, regulatory support and excellent supply chain reliability.
Mr Agostino Barazza, Chief Executive Officer of ICE Pharma, said: “This acquisition represents a very attractive opportunity to create the first fully vertically integrated global UDCA player & specialty API manufacturer, combining ICE’s well established international bile collection and API production network with ABC’s proven capabilities as a contract manufacturing organization (CMO) for FDF”.
Mr Alberto Giraudi, the current shareholder of ABC, will continue to play a role in the combined group as a minority shareholder and member of the board of directors of ICE S.p.A. Mr. Giraudi said: “ABC joins a large family with a global footprint, vertical integration and strong growth prospects unlocking new opportunities for the company and its employees. ABC will also become substantially more resilient and competitive for its UDCA CMO activities by joining one of the main UDCA API global players”.
The combined entity will enjoy substantial growth potential due to its ability to offer new products and services to existing and new customers.